	2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	5,865	6,214	7,782	8,749	10,260	12,207	14,278
Cost of Operating Revenue	2,102	2,026	2,740	3,397	3,761	4,340	4,938
Gross Profit	3,763	4,188	5,042	5,352	6,500	7,868	9,339
Gross Margin	64.2	67.4	64.8	61.2	63.3	64.4	65.4
Total Operating Expenses	4,437	4,661	5,949	7,161	8,119	9,801	11,546
Operating Profit	1,428	1,554	1,832	1,588	2,142	2,406	2,731
Operating Margin	24.4	25.0	23.5	18.2	20.9	19.7	19.1
Financing Income/(Expense) - Net	5	23	11	-20	19	-203	-639
Profit before Taxes	1,426	1,680	1,960	1,659	2,383	2,504	2,321
Income Taxes	382	399	522	362	457	510	395
Profit after Tax	1,030	1,265	1,433	1,282	1,913	1,991	1,913
PAT Margin	17.6	20.4	18.4	14.7	18.6	16.3	13.4
EPS - Basic - ex Extraordinary Items	25.72	31.59	35.78	32.00	47.73	49.17	46.35
EPS - Diluted - ex Extraordinary Items	25.72	31.59	35.78	32.00	47.66	49.08	46.28
EBIT	1,428	1,554	1,832	1,588	2,142	2,406	2,731
EBITDA	1,527	1,673	1,999	1,914	2,520	3,028	3,617
EBITDA Margin	26.0	26.9	25.7	21.9	24.6	24.8	25.3

Balance Sheet

Abridged

Understanding Balance Sheet

Mankind Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	2,822	3,907	4,407	4,328	6,568	6,988	6,954
Long-Term Investments	37	68	96	182	127	335	313
Property Plant & Equipment - Net	1,865	1,992	2,390	3,017	3,139	3,214	3,614
Total Non-Current Assets	2,251	2,466	4,741	5,388	5,395	20,771	21,125
Total Assets	5,073	6,373	9,148	9,715	11,963	27,760	28,080
Total Current Liabilities	1,259	1,353	2,623	1,863	2,120	5,664	6,507
Long Term Debt	53	62	52	28	33	5,540	2,893
Total Non-Current Liabilities	143	156	208	229	268	7,528	5,011
Total Liabilities	1,402	1,510	2,831	2,092	2,387	13,191	11,518
Total Shareholders' Equity	3,485	4,722	6,155	7,435	9,363	14,332	16,300
Minority Interest	186	141	161	188	213	236	261
Total Equity	3,672	4,863	6,316	7,623	9,576	14,568	16,561
Total Liabilities & Equity	5,073	6,373	9,148	9,715	11,963	27,760	28,080

Cash Flow

Abridged

Understanding Cash Flow Statement

Mankind Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1,210	1,254	1,501	1,617	2,146	2,521	2,405
Working Capital - Increase/(Decrease)	-145	-95	-586	167	20	-146	105
Net CF from Operating Activities	1,065	1,159	915	1,784	2,166	2,375	2,510
Capital Expenditures - Net	217	312	2,342	826	382	519	734
Net CF from Investing Activities	-456	-1,261	-1,382	-1,067	-2,122	-12,751	-254
Dividends Paid - Cash - Total	-	-	-	-	-	-	41
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	2,963	21
Debt - LT & ST - Issuance/(Retirement) - Total	-145	109	622	-698	31	7,367	-2,264
Net Cash Flow from Financing Activities	-509	9	622	-698	31	10,331	-2,284
Free Cash Flow to Equity	704	957	-805	260	1,816	9,223	-488
Free Operating CF net dividend	837	847	-1,431	952	1,777	1,844	1,732
Free Operating CF	837	847	-1,431	952	1,777	1,844	1,773

Business Segment Analysis

FY End:

Mar 25

Mankind Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

pharmaceuticals and other related products (100.0%)₹ 530.76 Cr

Revenue / Sales

pharmaceuticals and other related products (100.0%)₹ 12,207.44 Cr

Assets

pharmaceuticals and other related products (100.0%)₹ 27,759.53 Cr

Operating Income

pharmaceuticals and other related products (100.0%)₹ 2,406.43 Cr

Regional Segment Analysis

FY End:

Mar 25

Mankind Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Within India (87.4%)₹ 10,674.96 CrOutside India (12.6%)₹ 1,532.48 Cr

Historical Segment Analysis

Track how Mankind Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

pharmaceuticals and other related products	228	312	2,346	832	389	531

Frequently Asked Questions

What is the revenue of Mankind Pharma Ltd.?

The latest trailing twelve month revenue of Mankind Pharma Ltd. is ₹ 14,277.60 Cr, reflecting a 1-year growth of 16.96% and a 3-year CAGR of 17.73%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Mankind Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Mankind Pharma Ltd. is ₹ 1,912.93 Cr, with a 3-year earnings CAGR of 13.09%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Mankind Pharma Ltd.?

The trailing twelve month EBITDA of Mankind Pharma Ltd. is approximately ₹ 2,731.23 Cr (based on an operating margin of 19.13%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Mankind Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Mankind Pharma Ltd. is 46.28. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Mankind Pharma Ltd.?

The debt-to-equity ratio of Mankind Pharma Ltd. stands at 0.39. The interest coverage ratio is 4.27x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Mankind Pharma Ltd.?

The estimated book value per share of Mankind Pharma Ltd. is 399.00 (derived from a P/B ratio of 6.30 and market price of ₹ 2,514.10), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Mankind Pharma Ltd.?

The trailing twelve month operating cash flow of Mankind Pharma Ltd. is ₹ 2,510.30 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Mankind Pharma Ltd. report consolidated or standalone financials?

Mankind Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.